Bionomics Announces Intention to Delist From the Australian Securities Exchange (ASX)
Bionomics Announces Intention to Delist From the Australian Securities Exchange (ASX)
ADELAIDE, Australia and CAMBRIDGE, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or the Company) a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it has submitted a formal request to the Australian Securities Exchange ("ASX") to be removed from the official list of the ASX, in keeping with the Company's ongoing transformation to a U.S. focused organization. The main consequence of an ASX delisting for shareholders is that, from the time the proposed ASX delisting is scheduled to take effect on August 28, 2023, Bionomics Shares will no longer be quoted or traded on the ASX, and will only be tradable in the form of American Depositary Shares on the NASDAQ Global Market (NASDAQ) under the symbol BNOX.
澳大利亚阿德莱德和马萨诸塞州剑桥,2023年7月25日(GLOBE NEWSWIRE)— 生物学有限公司 (ASX: BNO,纳斯达克股票代码:BNOX)(Bionomics 或公司)是一家临床阶段的生物技术公司,正在开发新型、同类首创的变构离子通道调节剂,用于治疗患有严重中枢神经系统(CNS)疾病、医疗需求未得到满足的患者,该公司今天宣布,它已向澳大利亚证券交易所(“ASX”)提交了正式申请,要求将其从澳大利亚证券交易所的官方名单中删除,这与公司正在进行的向以美国为重点的组织的转型保持一致。澳大利亚证券交易所退市对股东的主要后果是,从拟议的澳大利亚证券交易所退市计划于2023年8月28日生效起,Bionomics股票将不再在澳大利亚证券交易所上市或交易,只能在纳斯达克全球市场(NASDAQ)以美国存托股票的形式交易,股票代码为BNOX。
"Bionomics is approaching several very important value-inflection milestones for our late-stage clinical development program with BNC210, a first and best-in class α7 nicotinic receptor negative allosteric modulator under evaluation in patients with Social Anxiety Disorder (SAD) and Post-Traumatic Stress Syndrome (PTSD), in the coming quarters," said Spyros Papapetropoulos, M.D. Ph.D., Bionomics' President and CEO; "As we continue our transformation to a U.S.-focused organization, we would like to deepen our engagement with the broadest range of potential investors and maximize Bionomics' access to capital and financing opportunities while reducing costs and compliance obligations associated with a dual listing. We believe delisting from the ASX and focusing on a primary listing on the NASDAQ will increase our trading volume and liquidity, and consequently will enable Bionomics to fulfill these objectives and support continued value creation for patients, investors, and our stakeholders."
Bionomics总裁兼首席执行官Spyros Papetropoulos医学博士说:“Bionomics正在接近我们后期临床开发计划的几个非常重要的价值转折里程碑,BNC210 是社交焦虑症(SAD)和创伤后应激综合症(PTSD)患者的首个也是同类中最好的 α7 烟碱受体阴性变构调节剂,正在评估中,” Bionomics 总裁兼首席执行官 Spyros Papetropoulos 医学博士说;“正如我们继续向以美国为重点的组织转型,我们希望以最广泛的潜力深化我们的参与投资者,最大限度地提高Bionomics获得资本和融资的机会,同时降低与双重上市相关的成本和合规义务。我们相信,从澳大利亚证券交易所退市并专注于在纳斯达克进行首次上市将增加我们的交易量和流动性,从而使Bionomics能够实现这些目标,支持患者、投资者和我们的利益相关者持续创造价值。”
Additional announcements will be made to the ASX, and notices will be sent to shareholders on the Australian share register, outlining the proposed delisting process and timeline, and their available options. All information will be made available at .
将向澳大利亚证券交易所发布其他公告,并将向澳大利亚股票登记册上的股东发送通知,概述拟议的退市流程和时间表及其可用的选择。所有信息将在以下网址公布 。
FOR FURTHER INFORMATION PLEASE CONTACT:
欲了解更多信息,请联系:
General | Investor Relations | Investor Relations |
Ms. Suzanne Irwin | Kevin Gardner | Chris Calabrese |
Company Secretary | kgardner@lifesciadvisors.com | ccalabrese@lifesciadvisors.com |
CoSec@bionomics.com.au |
普通的 | 投资者关系 | 投资者关系 |
苏珊娜·欧文女士 | 凯文·加德纳 | 克里斯·卡拉布雷斯 |
公司秘书 | kgardner@lifesciadvisors.com | ccalabrese@lifesciadvisors.com |
CoSec@bionomics.com.au |
About Bionomics Limited
Bionomics (ASX:BNO, NASDAQ:BNOX) is a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system ("CNS") disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions. Bionomics's pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need.
关于生物学有限公司
Bionomics(ASX: BNO,纳斯达克股票代码:BNOX)是一家处于临床阶段的生物技术公司,开发新型、同类首创的变构离子通道调节剂,用于治疗患有严重中枢神经系统(“CNS”)疾病、医疗需求未得到满足的患者。Bionomics正在推进其主要候选药物 BNC210,这是一种α7烟碱乙酰胆碱受体的口服专有选择性负变构调节剂,用于社交焦虑症(SAD)的急性治疗和创伤后应激障碍(PTSD)的慢性治疗。除了 BNC210 之外,Bionomics 还与默克公司(在美国和加拿大以外被称为 MSD)建立了战略合作伙伴关系,两种药物正在进行早期临床试验,用于治疗阿尔茨海默氏病和其他中枢神经系统疾病的认知缺陷。Bionomics的产品线还包括针对Kv3.1/3.2和Nav1.7/1.8离子通道的临床前资产,这些资产正在为需求高度未得到满足的中枢神经系统疾病而开发。
Forward Looking Statement
前瞻性声明
Bionomics cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company's plans to increase trading volume and liquidity, and advance the development of its product candidates, the timing of achieving any development or regulatory milestones, and the potential of such product candidates, including to achieve any benefit or profile or any product approval or be effective. The inclusion of forward-looking statements should not be regarded as a representation by Bionomics that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business and other risks described in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on October 14, 2022, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Bionomics undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included in Bionomics' filings with the SEC which are available from the SEC's website (www.sec.gov) and on Bionomics' website () under the heading "Investor Center." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Bionomics警告说,本新闻稿中包含的不是对历史事实描述的陈述是前瞻性陈述。诸如 “可能”、“可以”、“将”、“将”、“应该”、“期望”、“计划”、“预期”、“相信”、“估计”、“打算”、“预测”、“寻求”、“考虑”、“潜力”、“继续” 或 “项目” 之类的词语或这些术语或其他类似术语的否定词旨在识别前瞻性陈述。这些声明包括公司计划增加交易量和流动性,推进其候选产品的开发,实现任何开发或监管里程碑的时机,以及此类候选产品的潜力,包括实现任何收益或形象或任何产品批准或生效。纳入前瞻性陈述不应被视为Bionomics表示其任何计划都将实现。由于公司业务固有的风险和不确定性以及公司向美国证券交易委员会(SEC)提交的文件(包括公司于2022年10月14日向美国证券交易委员会提交的20-F表年度报告及其其他报告)中描述的其他风险,实际业绩可能与本新闻稿中列出的业绩存在重大差异。提醒投资者不要过分依赖这些前瞻性陈述,这些陈述仅代表截至本文发布之日,Bionomics没有义务修改或更新本新闻稿以反映本新闻稿发布之日之后的事件或情况。有关这些风险和其他风险的更多信息包含在Bionomics向美国证券交易委员会提交的文件中,这些文件可在美国证券交易委员会的网站(www.sec.gov)和Bionomics网站()上的 “投资者中心” 标题下查阅。所有前瞻性陈述均受本警示性声明的全部限制。这种谨慎态度是根据1995年《私人证券诉讼改革法》第21E条的安全港规定提出的。